Markets
RedHill Biopharma Ltd. (RDHL)
RDHLNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$0.3803
+0.0045 (+1.20%) today
Closed, Nov 13, 4:00 PM ET
+1.20% 1D
- Market cap
- $3.33m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.3601 to $1.60
- Average volume
- –
- Previous close
- $0.3758
Financials
| Quarter | Dec 2012 |
|---|---|
| Revenue | $4,000 |
| Gross profit | $4,000 |
| Operating income | -$2.12m |
| Net income | -$3.35m |
News
5 latest- RedHill Biopharma Ltd. Regains ex-North America Rights to RHB-102Fintel · Oct 21, 2026
- RedHill: FDA Grants Rare Pediatric Disease Designation To Opaganib RTTNews · Jun 9, 2026
- RedHill To Submit UK MAA For Talicia For H. Pylori Infection, Referencing FDA Approval; Stock Down RTTNews · Mar 18, 2025
- RedHill Licenses RHB-102 To Hyloris For Worldwide Commercialization Excluding North America RTTNews · Feb 25, 2025
- RedHill Biopharma Launches Phase 2 Trial For Advanced Prostate Cancer Treatment RTTNews · Feb 4, 2025
The company
RedHill Biopharma Ltd. (NASDAQ: RDHL) is a U.S. specialty biopharmaceutical company primarily focused on the development and commercialization of proprietary drugs for gastrointestinal diseases, infectious diseases and oncology. RedHill promotes the FDA-approved gastrointestinal therapies Rebyota , for the prevention of recurrent C. diff infection (rCDI), and the bowel preparation treatment, Clenpiq .
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- Middle East
- Website
- redhillbio.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.